LVADs held a 74.3% share of the artificial heart market in 2025, reflecting their established role in supporting patients with advanced heart failure while preserving part of the native heart’s function. This leadership is maintained through their broader clinical familiarity, wider use across treatment pathways, and practical fit for patients who need mechanical circulatory support without full heart replacement. In the artificial heart market, LVADs remain the leading type because they are more deeply embedded in care protocols and are applicable to a larger treated population than more intensive replacement-based options.

Total Artificial Heart is the fastest-growing segment in the artificial heart market as demand rises for solutions suited to patients with severe biventricular failure where partial support is not sufficient. Its momentum is being encouraged by the need for complete cardiac replacement in critical cases, especially when conventional ventricular assist approaches are not clinically adequate. Compared with LVAD-based support, Total Artificial Heart is gaining traction because it addresses a narrower but more acute treatment requirement that is becoming more visible in advanced end-stage heart disease management.

Therapy Segment Analysis: Bridge To Transplant (Largest Segment) vs Destination Therapy (Fastest-Growing Segment)

Within the artificial heart market, Bridge To Transplant accounted for the largest share in 2025, reinforced through its close alignment with established transplant pathways for patients awaiting donor availability. Its dominant position comes from the practical role artificial heart therapies play in stabilizing patients during often unpredictable waiting periods, helping maintain circulation until transplantation becomes possible. This keeps Bridge To Transplant at the center of current therapy use, especially where mechanical support is integrated into transplant-centered cardiac care.

Destination Therapy is the fastest-growing therapy segment in the artificial heart market because it serves patients who are not eligible for transplant and therefore require longer-term mechanical support as a definitive treatment approach. Growth is being shaped by the practical expansion of treatment demand beyond transplant candidates, with clinicians increasingly using artificial heart solutions for sustained management rather than temporary bridging alone. Relative to Bridge To Transplant, Destination Therapy is gaining momentum as the market responds to a broader patient pool that needs ongoing support without dependence on donor heart availability.